Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 6/20 | 0.79 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | AXL | P30530 | 4/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | KIT | P10721 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.67 |
| ▸ | MERTK | Q12866 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137050 | 0.94 | MET (0.89) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL1137557 | 0.88 | MET (0.79) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL23999220 | 0.86 | MET (0.76) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL26621294 | 0.85 | MET (0.74) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL29843369 | 0.85 | MET (0.74) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL23999234 | 0.85 | MET (1.00) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL1137343 | 0.84 | MET (1.00) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL12863936 | 0.84 | MET (0.88) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL12350006 | 0.83 | MET (0.71) | METRIPK3RIPK1RIPK2CYP3A4 | |
| SCHEMBL1137224 | 0.83 | MET (0.71) | METRIPK3RIPK1RIPK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989477-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | claimed |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | claimed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | claimed |
| US-8536200-B2 | Pyridinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2089364-B1 | PYRIDINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2235002-B1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2012-11-21 | — | — | EP | disclosed |
| US-8258118-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258118-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-04 | — | — | US | disclosed |
| US-20120114643-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-20120114643-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-8124768-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-26 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| WO-2008058229-A1 | PYRIDINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054436-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | MET 162/4885RIPK3 489/4885RIPK1 558/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | MET 162/4885RIPK3 489/4885RIPK1 558/4885 |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | MET, HGF, DCK | MET 1/4885RIPK3 1015/4885RIPK1 918/4885 |
| US-20100183606-A1 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | CDK2, MAP3K19, CDK1 | MET 162/4885RIPK3 489/4885RIPK1 558/4885 |
| US-20120114643-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | DPYD, CDK4, G6PD | MET 3606/4885RIPK3 3842/4885RIPK1 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.